Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain

• Váldodahkkit: R. Ariza (Dahkki), A. van Walsem (Dahkki), C. Canal (Dahkki), C. Roldán (Dahkki), L. Betegón (Dahkki), I. Oyagüez (Dahkki), K. Janssen (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2014-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous abatacept was considered comparable to intrave...